Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00227773
First received: September 26, 2005
Last updated: October 6, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given